NDAORALCAPSULE, EXTENDED RELEASE
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VERELAN PM (verapamil hydrochloride) by R-Pharm US is (l-type calcium channel blocker or calcium channel antagonist). First approved in 1998.
Drug data last refreshed 25m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Verelan PM is an extended-release oral formulation of verapamil hydrochloride, an L-type calcium channel blocker approved in 1998. It reduces arterial smooth muscle contractility and cardiac conduction by selectively inhibiting calcium ion influx, used primarily for hypertension and angina management. The PM (evening) formulation is designed to deliver peak levels overnight, aligning with circadian blood pressure patterns.
$0.12MPart D
LOE ApproachingDeclining
Brand faces imminent loss of exclusivity with minimal Part D uptake (269 claims in 2023), signaling a sunset phase requiring defensive commercial strategies and possible portfolio transition planning.
Mechanism of Action
(L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Verelan PM offers limited growth trajectory and career advancement; roles focus on defending market share against generics, managing payer relationships, and optimizing margins on a declining asset. This is a defensible but transitional position, suitable for professionals building operational expertise in mature product management or seeking stable income in a portfolio context.
Worked on VERELAN PM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.